A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

Tine Thurison; Anne F Lomholt; Morten G Rasch; Ida K Lund; Hans J Nielsen; Ib J Christensen; Gunilla Høyer-Hansen; Anne Fog Lomholt

doi:10.1373/clinchem.2010.144410

A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

Tine Thurison, Anne F Lomholt, Morten G Rasch, Ida K Lund, Hans J Nielsen, Ib J Christensen, Gunilla Høyer-Hansen, Anne Fog Lomholt

Research output: Contribution to journal › Journal article › Research › peer-review

31 Citations (Scopus)

Abstract

The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.

Original language	English
Journal	Clinical Chemistry
Volume	56
Issue number	10
Pages (from-to)	1636-40
Number of pages	5
ISSN	0009-9147
DOIs	https://doi.org/10.1373/clinchem.2010.144410
Publication status	Published - 1 Oct 2010

Access to Document

10.1373/clinchem.2010.144410

Cite this

A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. / Thurison, Tine; Lomholt, Anne F; Rasch, Morten G; Lund, Ida K; Nielsen, Hans J; Christensen, Ib J; Høyer-Hansen, Gunilla; Lomholt, Anne Fog.

In: Clinical Chemistry, Vol. 56, No. 10, 01.10.2010, p. 1636-40.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{b325fb9a077b421d936f4a694608662d,

title = "A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer",

abstract = "The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.",

author = "Tine Thurison and Lomholt, {Anne F} and Rasch, {Morten G} and Lund, {Ida K} and Nielsen, {Hans J} and Christensen, {Ib J} and Gunilla H{\o}yer-Hansen and Lomholt, {Anne Fog}",

year = "2010",

month = oct,

day = "1",

doi = "10.1373/clinchem.2010.144410",

language = "English",

volume = "56",

pages = "1636--40",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry, Inc.",

number = "10",

}

TY - JOUR

T1 - A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

AU - Thurison, Tine

AU - Lomholt, Anne F

AU - Rasch, Morten G

AU - Lund, Ida K

AU - Nielsen, Hans J

AU - Christensen, Ib J

AU - Høyer-Hansen, Gunilla

AU - Lomholt, Anne Fog

PY - 2010/10/1

Y1 - 2010/10/1

N2 - The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.

AB - The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.

U2 - 10.1373/clinchem.2010.144410

DO - 10.1373/clinchem.2010.144410

M3 - Journal article

C2 - 20802096

VL - 56

SP - 1636

EP - 1640

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 10

ER -